Inhibition of Ubiquitin-specific Protease 4 Attenuates Epithelial—Mesenchymal Transition of Renal Tubular Epithelial Cells via Transforming Growth Factor Beta Receptor Type I

Abstract

Objective

Ubiquitin-specific protease 4 (USP4) facilitates the development of transforming growth factor-beta 1 (TGF-β1)-induced epithelial-mesenchymal transition (EMT) in various cancer cells. Moreover, EMT of renal tubular epithelial cells (RTECs) is required for the progression of renal interstitial fibrosis. However, the role of USP4 in EMT of RTECs remains unknown. The present study aimed to explore the effect of USP4 on the EMT of RTECs as well as the involved mechanism.

Methods

In established unilateral ureteral obstruction (UUO) rats and NRK-52E cells, immunohistochemistry and Western blot assays were performed.

Results

USP4 expression was increased significantly with obstruction time. In NRK-52E cells stimulated by TGF-β1, USP4 expression was increased in a time-dependent manner. In addition, USP4 silencing with specific siRNA indicated that USP4 protein was suppressed effectively. Meanwhile, USP4 siRNA treatment restored E-cadherin and weakened alpha smooth muscle actin (α-SMA) expression, indicating that USP4 may promote EMT. After treatment with USP4 siRNA and TGF-β1 for 24 h, the expression of TGF-β1 receptor type I (TβRI) was decreased.

Conclusion

USP4 promotes the EMT of RTECs through upregulating TβRI, thereby facilitating renal interstitial fibrosis. These findings may provide a potential target of USP4 in the treatment of renal fibrosis.

Keywords

ubiquitin-specific protease 4 / renal tubular epithelial cells / epithelial-mesenchymal transition / transforming growth factor-beta 1 receptor type I / renal interstitial fibrosis

References

[1] PanizoS, Martínez-AriasL, Alonso-MontesC, et al.. Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. Int J Mol Sci, 2021, 22(1): 408

[2] LiuBC, TangTT, LvLL. How Tubular Epithelial Cell Injury Contributes to Renal Fibrosis. Adv Exp Med Biol, 2019, 1165: 233-252

[3] HumphreysBD. Mechanisms of Renal Fibrosis. Annu Rev Physiol, 2018, 80: 309-326

[4] ShengLL, ZhuangSG. New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis. Front Physiol, 2020, 11: 569322

[5] YuanQ, TanRJ, LiuY. Myofibroblast in Kidney Fibrosis: Origin, Activation, and Regulation. Adv Exp Med Biol, 2019, 1165: 253-283

[6] Ruiz-OrtegaM, Rayego-MateosS, LamasS, et al.. Targeting the progression of chronic kidney disease. Nat Rev Nephrol, 2020, 16(5): 269-288

[7] FaktorJ, PjechováM, HernychováL, et al.. Protein Ubiquitination Research in Oncology. Klin Onkol, 2019, 32: 56-64

[8] SongL, LuoZQ. Post-translational regulation of ubiquitin signaling. J Cell Biol, 2019, 218(6): 1776-1786

[9] LiO, MaQ, LiF, et al.. Progress of small ubiquitin-related modifiers in kidney diseases. Chin Med J (Engl), 2019, 132(4): 466-473

[10] Meyer-SchwesingerC. The ubiquitin-proteasome system in kidney physiology and disease. Nat Rev Nephrol, 2019, 15(7): 393-411

[11] YoungMJ, HsuKC, LinTE, et al.. The role of ubiquitin-specific peptidases in cancer progression. J Biomed Sci, 2019, 26(1): 42

[12] LaiKP, ChenJ, TseWKF. Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy. Int J Mol Sci, 2020, 21(7): 2548

[13] HuB, ZhangD, ZhaoK, et al.. Spotlight on USP4: Structure, Function, and Regulation. Front Cell Dev Biol, 2021, 9: 595159

[14] WangY, ZhouL, LuJ, et al.. USP4 function and multifaceted roles in cancer: a possible and potential therapeutic target. Cancer Cell Int, 2020, 20: 298

[15] Martínez-KlimovaE, Aparicio-TrejoOE, TapiaE, et al.. Unilateral Ureteral Obstruction as a Model to Investigate Fibrosis-Attenuating Treatments. Biomolecules, 2019, 9(4): 141

[16] LovisaS, ZeisbergM, KalluriR. Partial Epithelial-to-Mesenchymal Transition and Other New Mechanisms of Kidney Fibrosis. Trends Endocrinol Metab, 2016, 27(10): 681-695

[17] PuJY, ZhangY, ZhouJH. Effect of Huai Qi Huang on Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells through miR-200a. Evid Based Complement Alternat Med, 2016, 2016: 8612190

[18] LiuBC, TangTT, LvLL, et al.. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int, 2018, 93(3): 568-579

[19] ZhangL, ChenQ, ChenZ, et al.. Mechanisms Regulating Muscle Protein Synthesis in CKD. J Am Soc Nephrol, 2020, 31(11): 2573-2587

[20] GaiZ, ZhouG, GuiT, et al.. Trps1 haploinsufficiency promotes renal fibrosis by increasing Arkadia expression. J Am Soc Nephrol, 2010, 21(9): 1468-1476

[21] ChenL, YangT, LuDW, et al.. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. Biomed Pharmacother, 2018, 101: 670-681

[22] CuiTG, IchikawaT, YangM, et al.. An emerging role of deubiquitinating enzyme cylindromatosis (CYLD) in the tubulointerstitial inflammation of IgA nephropathy. Biochem Biophys Res Commun, 2009, 390(2): 307-312

[23] HuangK, ZhaoX. USP9X prevents AGEs-induced upregulation of FN and TGF-β1 through activating Nrf2-ARE pathway in rat glomerular mesangial cells. Exp Cell Res, 2020, 393(2): 112100

[24] SojiK, DoiS, NakashimaA, et al.. Deubiquitinase inhibitor PR-619 reduces Smad4 expression and suppresses renal fibrosis in mice with unilateral ureteral obstruction. PloS One, 2018, 13(8): e0202409

[25] HeB, ZhaoYC, GaoLC, et al.. Ubiquitin-Specific protease 4 is an endogenous negative regulator of pathological cardiac hypertrophy. Hypertension, 2016, 67(6): 1237-1248

[26] XuJ, ChenD, JinL, et al.. Ubiquitously specific protease 4 inhibitor-Vialinin A attenuates inflammation and fibrosis in S100-induced hepatitis mice through Rheb/mTOR signalling. J Cell Mol Med, 2021, 25(2): 1140-1150

[27] ZhangJ, NaS, PanS, et al.. Inhibition of USP4 attenuates pathological scarring by downregulation of the TGF-β/Smad signaling pathway. Mol Med Rep, 2019, 20(2): 1429-1435

[28] LiF, HuQ, HeT, et al.. The Deubiquitinase USP4 stabilizes Twist1 protein to promote lung cancer cell stemness. Cancers (Basel), 2020, 12(6): 1582

[29] QiuC, LiuY, MeiY, et al.. Ubiquitin-specific protease 4 promotes metastasis of hepatocellular carcinoma by increasing TGF-β signaling-induced epithelial-mesenchymal transition. Aging (Albany NY), 2018, 10(10): 2783-2799

[30] XiaoL, PengX, LiuF, et al.. AKT regulation of mesothelial-to-mesenchymal transition in peritoneal dialysis is modulated by Smurf2 and deubiquitinating enzyme USP4. BMC Cell Biol, 2015, 16: 7

[31] QinN, HanF, LiL, et al.. Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity. Oncol Lett, 2019, 17(1): 958-964

[32] ZhouY, LiangP, JiW, et al.. Ubiquitin-specific protease 4 promotes glioblastoma multiforme via activating ERK pathway. Onco Targets Ther, 2019, 12: 1825-1839

[33] LiT, YanB, MaY, et al.. Ubiquitin-specific protease 4 promotes hepatocellular carcinoma progression via cyclophilin A stabilization and deubiquitination. Cell Death Dis, 2018, 9(2): 148

[34] MaTT, MengXM. TGF-β/Smad and Renal Fibrosis. Adv Exp Med Biol, 2019, 1165: 347-364

[35] GuYY, LiuXS, HuangXR, et al.. Diverse role of TGF-β in kidney disease. Front Cell Dev Biol, 2020, 8: 123

[36] AhmadiA, NajafiM, FarhoodB, et al.. Transforming growth factor-β signaling: Tumorigenesis and targeting for cancer therapy. J Cell Physiol, 2019, 234(8): 12173-12187

[37] Vander ArkA, CaoJ, LiX. TGF-β receptors: In and beyond TGF-β signaling. Cell Signal, 2018, 52: 112-120

[38] KimSY, BaekKH. TGF-β signaling pathway mediated by deubiquitinating enzymes. Cell Mol Life Sci, 2019, 76(4): 653-665

[39] VlasschaertC, XiaX, CoulombeJ, et al.. Evolution of the highly networked deubiquitinating enzymes USP4, USP15, and USP11. BMC Evol Biol, 2015, 15: 230

[40] ZhangL, ZhouF, DrabschY, et al.. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat Cell Biol, 2012, 14(7): 717-726

[41] LiaoW, LiangP, LiuB, et al.. MicroRNA-140-5p mediates renal fibrosis through TGF-β1/Smad signaling pathway by directly targeting TGFBR1. Front Physiol, 2020, 11: 1093